Nothing Special   »   [go: up one dir, main page]

ATE211762T1 - Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1) - Google Patents

Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1)

Info

Publication number
ATE211762T1
ATE211762T1 AT94916170T AT94916170T ATE211762T1 AT E211762 T1 ATE211762 T1 AT E211762T1 AT 94916170 T AT94916170 T AT 94916170T AT 94916170 T AT94916170 T AT 94916170T AT E211762 T1 ATE211762 T1 AT E211762T1
Authority
AT
Austria
Prior art keywords
beta1
tgf
growth factor
transforming growth
treating
Prior art date
Application number
AT94916170T
Other languages
English (en)
Inventor
Georg-Ferdinan Schlingensiepen
Wolfgang Brysch
Karl-Hermann Schlingensiepen
Reimar Schlingensiepen
Ulrich Bogdahn
Original Assignee
Biognostik Ges
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biognostik Ges filed Critical Biognostik Ges
Application granted granted Critical
Publication of ATE211762T1 publication Critical patent/ATE211762T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT94916170T 1993-04-30 1994-04-29 Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1) ATE211762T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP93107089 1993-04-30
EP93107849 1993-05-13
PCT/EP1994/001362 WO1994025588A2 (en) 1993-04-30 1994-04-29 ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE EFFECTS OF TRANSFORMING GROWTH FACTOR-β (TGF-β)

Publications (1)

Publication Number Publication Date
ATE211762T1 true ATE211762T1 (de) 2002-01-15

Family

ID=26133181

Family Applications (2)

Application Number Title Priority Date Filing Date
AT94916170T ATE211762T1 (de) 1993-04-30 1994-04-29 Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1)
AT99125278T ATE235549T1 (de) 1993-04-30 1994-04-29 Antisense oligonukleotide zur behandlung von immunsuppressiven wirkungen von tgf-beta2

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT99125278T ATE235549T1 (de) 1993-04-30 1994-04-29 Antisense oligonukleotide zur behandlung von immunsuppressiven wirkungen von tgf-beta2

Country Status (6)

Country Link
US (3) US6455689B1 (de)
JP (2) JP3555952B2 (de)
AT (2) ATE211762T1 (de)
AU (1) AU6794594A (de)
DE (2) DE69432375T2 (de)
WO (1) WO1994025588A2 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884787B2 (en) 2001-07-14 2005-04-26 Isis Pharmaceuticals, Inc. Antisense modulation of transforming growth factor-beta 3 expression
WO1995000103A2 (en) * 1993-06-15 1995-01-05 Il-Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
US5772995A (en) * 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
ATE343638T1 (de) * 1995-06-02 2006-11-15 Gilead Sciences Inc Oligonukleotidliganden mit hoher affinität für pdgf
DE19613691A1 (de) * 1996-04-05 1997-10-09 Boehringer Ingelheim Int Arzneimittel für die Behandlung von Tumorerkrankungen
EP0856579A1 (de) 1997-01-31 1998-08-05 BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH Ein Verfahren zur Zubereitung von Antisense Oligonukleotiden
CA2334960C (en) 1998-06-10 2012-01-03 Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh Combination of tgf-.beta. inhibition and immune stimulation to treat hyperproliferative diseases
FR2790955B1 (fr) * 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
CA2381006A1 (en) * 1999-09-17 2001-03-22 Nicholas M. Dean Antisense modulation of transforming growth factor-.beta. expression
EP1133988A1 (de) 2000-03-11 2001-09-19 Biognostik Gesellschaft für biomolekulare Diagnostik mbH Mischung enthaldend einen Inhibitor oder Suppressor von einen Gens und eine Moleküle bindende des Expressionprodukt des Gens
US7101543B2 (en) * 2000-03-31 2006-09-05 Novarx Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells
ATE554169T1 (de) * 2001-11-02 2012-05-15 Giuliani Int Ltd Smad7-inhibitoren zur behandlung von krankheiten des zns
KR20030056538A (ko) * 2001-12-28 2003-07-04 주식회사 웰진 리본형 안티센스 올리고뉴클레오티드에 의한 형질전이성장 인자-β1의 효과적 저해제 개발
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
CA2506236C (en) * 2002-11-18 2018-07-17 Vicuron Pharmaceuticals Inc. Compositions and uses of dalbavancin for treatment of bacterial infections
US20070080480A1 (en) * 2003-03-03 2007-04-12 Rick Tabor Method for reducing the allergenic protein content of natural rubber latex articles
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
US7750142B2 (en) * 2003-04-28 2010-07-06 Isis Pharmaceuticals, Inc. Modulation of glucagon receptor expression
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
US20050036994A1 (en) * 2003-07-16 2005-02-17 Koichiro Mihara Compounds and methods for downregulating the effects of TGF-beta
WO2005059133A2 (en) * 2003-12-19 2005-06-30 Antisense Pharma Gmbh Combination therapy associating a tgf-breta antagonist with a chemiotherapeutic agent
EP2248895B8 (de) * 2003-12-19 2016-09-21 Autotelic LLC Kombinations-therapie die ein TGF-beta Antagonisten mit einem Chemotherapeutikum assoziiert
US20050245508A1 (en) * 2003-12-24 2005-11-03 Scios, Inc. Treatment of malignant gliomas with TGF-beta inhibitors
EP1568383A3 (de) * 2004-02-27 2005-11-16 Antisense Pharma GmbH Verwendung eines Oligonukleotide oder seiner aktiven Ableitung für die Zubereitung einer pharmazeutische Zusammensetzung zur Hemmung der Metastasenbildung in Krebsbehandlung
WO2005084712A2 (en) * 2004-02-27 2005-09-15 Antisense Pharma Gmbh Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
DE102004025881A1 (de) * 2004-05-19 2006-01-05 Beiersdorf Ag Oligoribonukleotide zur Beeinflussung des Haarwachstums
EP1877070B1 (de) * 2005-05-05 2008-12-31 Antisense Pharma GmbH Verwendung von tgf-beta2 antisense oligonukleotiden
KR20080074101A (ko) * 2005-09-19 2008-08-12 존슨 앤드 존슨 파머슈티컬 리서치 앤드 디벨로프먼트 엘엘씨 글루카곤 수용체 발현의 조절
EP1948675B1 (de) 2005-10-25 2014-07-30 The Johns Hopkins University Verfahren und zusammensetzungen zur behandlung von marfan-syndrom und verwandten erkrankungen
US8454952B2 (en) 2006-03-13 2013-06-04 The Johns Hopkins University Augmentation of endothelial thromboresistance
CN104645328A (zh) 2006-10-03 2015-05-27 建新公司 TGF-β拮抗物治疗具有罹患支气管肺发育不良风险的婴儿的用途
US8822425B2 (en) * 2008-11-14 2014-09-02 Antisense Pharma Gmbh Dosage of oligonucleotides suitable for the treatment of tumors
EP2524038A4 (de) * 2010-01-12 2013-11-20 Isis Pharmaceuticals Inc Modulation der transformierung einer wachstumsfaktor-beta-1-expression
SI3117709T1 (sl) 2010-03-12 2018-12-31 Genzyme Corporation Kombinirana terapija za zdravljenje raka dojke
EP2580326A1 (de) 2010-06-11 2013-04-17 Antisense Pharma GmbH Verfahren zur selektiven oligonukleotidmodifikation
EP2660314A4 (de) 2010-12-27 2014-09-03 Lsip Llc Ips-zellen und verfahren zu ihrer erzeugung
EP2737083A1 (de) 2011-07-27 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Scientifique) Verfahren zur diagnose und behandlung des myhre-syndroms
CN108410868A (zh) 2011-09-20 2018-08-17 Ionis制药公司 Gcgr表达的反义调节
BR112014009789A2 (pt) 2011-10-26 2017-04-25 Seattle Children's Res Inst cisteamina no tratamento da doença fibrótica
ES2897740T3 (es) 2011-12-28 2022-03-02 Kyoto Prefectural Public Univ Corp Normalización del cultivo de células endoteliales de la córnea
EP2812443B1 (de) 2012-02-06 2019-05-29 Inhibrx, Inc. Cd47-antikörper und verfahren zur verwendung davon
CA2908105C (en) * 2013-03-27 2021-07-27 Isarna Therapeutics Gmbh Modified tgf-beta2 oligonucleotides
PL2978846T3 (pl) 2013-03-27 2020-09-21 Isarna Therapeutics Gmbh Zmodyfikowany oligonukleotyd tgf-beta do zastosowania w sposobie zapobiegania i/lub leczenia choroby oftalmicznej
JP6492053B2 (ja) 2013-03-27 2019-03-27 イサルナ セラピューティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 修飾ｔｇｆ−ベータオリゴヌクレオチド
PL3064222T3 (pl) 2013-10-31 2021-04-19 Kyoto Prefectural Public University Corporation Lek terapeutyczny zawierający inhibitor sygnału tgf-beta w chorobach związanych z retikulum endoplazmatycznym i śmiercią komórki w śródbłonku rogówki
WO2016187312A1 (en) 2015-05-18 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
WO2017138924A1 (en) 2016-02-09 2017-08-17 Autotelic Llc Compositions and methods for treating pancreatic cancer
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
KR20220039639A (ko) 2020-09-21 2022-03-29 오토텔릭바이오 주식회사 안티센스 올리고뉴클레오타이드

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU626524B2 (en) * 1987-05-29 1992-08-06 Bristol-Myers Squibb Company Cloning and expression of simian transforming growth factor- beta 1
US5221620A (en) * 1987-10-06 1993-06-22 Oncogen Cloning and expression of transforming growth factor β2
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5525468A (en) * 1992-05-14 1996-06-11 Ribozyme Pharmaceuticals, Inc. Assay for Ribozyme target site
US5596072A (en) * 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
US5464945A (en) * 1992-08-28 1995-11-07 Hoffmann-La Roche Inc. Oligonucleotide probes specific for the human alpha satellite locus

Also Published As

Publication number Publication date
US6455689B1 (en) 2002-09-24
DE69432375D1 (de) 2003-04-30
DE69429617D1 (de) 2002-02-14
JPH08509370A (ja) 1996-10-08
US7667027B2 (en) 2010-02-23
WO1994025588A2 (en) 1994-11-10
AU6794594A (en) 1994-11-21
WO1994025588A3 (en) 1994-12-22
JP3555952B2 (ja) 2004-08-18
DE69429617T2 (de) 2002-08-22
JP2004024264A (ja) 2004-01-29
DE69432375T2 (de) 2004-02-12
JP3600831B2 (ja) 2004-12-15
US20030040499A1 (en) 2003-02-27
ATE235549T1 (de) 2003-04-15
US20080214483A1 (en) 2008-09-04

Similar Documents

Publication Publication Date Title
ATE211762T1 (de) Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1)
EP1762619A3 (de) Multi-tumor abweichende wachstumsgene
FI951612A0 (fi) Menetelmiä synteettisten oligonukleotidien sekvensoimiseksi, jotka sisältävät nukleotidien välisiä ei-fosfodiesterisidoksia
CA2048450A1 (en) Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
CA2200371A1 (en) Human npik gene
NO983716D0 (no) Metoksyetoksy oligonukleotider for modulering av protein-kinase C ekspresjon
EP0702694A4 (de) $i(PSEUDOMONAS SYRINGAE) pv. $i(SYRINGAE hrpY)-GEN
WO1996038473A3 (en) Antimicrobial cationic peptides
EP1008649A3 (de) Antisense Oligonukleotide zur Behandlung von Immunosuppressive Wirkungen von TGF-beta2
CY1106978T1 (el) Ενζυμα φωσφοδιεστερασης
NZ508439A (en) Novel endometriosis-associated gene
DE68926455D1 (de) Verfahren zur identifizierung von bakterien
EP0967283A4 (de) Gene, die für proteine mit transglykolysierungsaktivität kodieren.
PL317046A1 (en) Endotransglycosidase to tomato xyloglucane
ATE348158T1 (de) Neuartiges collectin
AU6144294A (en) Plant virus resistance conferring polyribozyme and resistant plants producing same
DE59611131D1 (de) Acarbose-Biosynthesegene aus Actinoplanes sp., Verfahren zu ihrer Isolierung sowie ihrer Verwendung
GB9615498D0 (en) Kinase
IT1255666B (it) Sequenze nucleotidiche codificanti per una dna polimerasi.
ES2109373T3 (es) Nueva proteina inhibidora de trombina a partir de garrapatas.
CA2419038A1 (en) Nucleic acid and protein increasing expression levels under salt stress
TH52857A (th) แบคทีเรียของสกุล Bacillus และโปรตีนสำหรับฆ่าแมลง
CA2247087A1 (en) Flower organ-specific gene and its promoter sequence

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification